Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Year Ended December 31, 

    

2023

    

2022

Revenue

Qbrexza

$

25,410

$

26,715

Accutane

20,168

18,373

Amzeeq

6,201

7,242

Zilxi

1,962

2,273

Targadox

3,204

7,972

Exelderm

2,395

3,463

Ximino

287

4,957

Luxamend

35

Collaboration revenue

5,229

1,882

Revenue – related party

 

103

 

192

Other revenue

19,519

 

2,674

Total net revenue

$

84,513

$

75,743